{ "ok": true, "cik": "1937653", "ticker": "ZYME", "name": "ZYMEWORKS INC.", "filings": [ { "form": "8-K", "filed": "2026-09-23", "items": [ "1.01 Entry into a Material Definitive Agreement", "2.01 Completion of Acquisition or Disposition of Assets", "2.03 Creation of a Direct Financial Obligation", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1937653/000119312526399383/0001193125-26-399383-index.htm" }, { "form": "8-K", "filed": "2026-08-25", "items": [ "7.01 Regulation FD Disclosure", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1937653/000193765326000051/0001937653-26-000051-index.htm" }, { "form": "10-Q", "filed": "2026-08-06", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1937653/000193765326000047/0001937653-26-000047-index.htm" }, { "form": "8-K", "filed": "2026-08-06", "items": [ "2.02 Results of Operations and Financial Condition", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/0001937653-26-000046-index.htm" }, { "form": "8-K", "filed": "2026-06-29", "items": [ "1.01 Entry into a Material Definitive Agreement", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1937653/000119312526286829/0001193125-26-286829-index.htm" }, { "form": "8-K", "filed": "2026-05-14", "items": [ "7.01 Regulation FD Disclosure", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1937653/000119312526224161/0001193125-26-224161-index.htm" } ], "events12m": 14, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001937653.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1937653" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up ZYMEWORKS INC. ($ZYME). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-09-23. 14 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 105965000, "revenueGrowth1y": 0.3887214300691968, "revenueGrowthPerYear": 0.41170565465651143, "yearsOfData": 5, "operatingMargin": -0.8733921577879489, "operatingMarginPrior": -1.7968913818410568, "netMargin": -0.7656301609021847, "operatingCashFlow": -33005000, "capitalSpending": 1521000, "freeCashFlow": -34526000, "researchAndDevelopment": 137000000, "researchShareOfRevenue": 1.2928797244373142, "cash": 41157000, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 26680000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 412482000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 76012000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 76304000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 105965000 } ], "totalEquity": 268501000, "totalAssets": 346527000, "equityRatio": 0.774834284197191, "returnOnEquity": -0.30215902361629937, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": -1.08, "sharesOutstanding": 75413396, "bookValuePerShare": 3.560388660921728, "revenuePerShare": 1.4051217107369094, "range80": { "low": 83047951.11624263, "high": 133543129.2937796, "baseline": 107258929.27355787, "n": 4309, "band": "b01", "bandLabel": "$100M–1B", "method": "v4.1", "credibility": 0.25, "growthYears": 2, "ownVolatility": 0.22949104646635365, "classVolatility": 0.1022985825903761, "volatility": 0.14496649648127502 }, "ifPaceHeld": { "low": 83047951.11624263, "high": 133543129.2937796 } }, "edgarette": "🔖 Exposure: revenue $106.0M (FY2025). Experience: revenue up 38.9% on the year, up 41.2% a year over 4 years; operating margin -87.3%, up from -179.7%. Soundness: equity 77.5% of assets, return on equity -30.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $83.0M and $133.5M next year (method v4.1: its own 2-year record of growth weighed at 25% against $100M–1B filers; on a year the method never saw, 83.4% landed inside). In a shock year the stress range is $73.6M to $151.3M. A range, not a forecast. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -87.3% against a -3.8% median; growth 38.9% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Zymeworks (ZYME) grew revenue 38.9% in FY2025 to $106 million, operating margin -87.3% against a -3.8% median for pharmaceutical preparations, equity 77.5% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
ZYMEWORKS INC. against its own record and its peers
Operating marginPeer median -3.8%-87.3%Revenue, on the yearPeer median 13.7%38.9%Equity of assetsPeer median 40.3%77.5%Return on equityPeer median -1.1%-30.2%Gold tick: the median of 100–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 2, "hits": 2, "rate": 1, "method": "v4", "byYear": { "2024": [ 1, 1 ], "2025": [ 1, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-24T14:19:37.798Z", "hash": "1e71ac1caf08ef64", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Zymeworks (ZYME) grew revenue 38.9% in FY2025 to $106 million, operating margin -87.3% against a -3.8% median for pharmaceutical preparations, equity 77.5% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 105965000, "totalDebt": null, "cash": 41157000 }, "experience": { "revenueGrowth1y": 0.3887214300691968, "revenueGrowthPerYear": 0.41170565465651143, "operatingMargin": -0.8733921577879489, "operatingMarginPrior": -1.7968913818410568, "netMargin": -0.7656301609021847, "freeCashFlow": -34526000 }, "soundness": { "equityRatio": 0.774834284197191, "returnOnEquity": -0.30215902361629937, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": { "low": 83047951.11624263, "high": 133543129.2937796, "baseline": 107258929.27355787, "coverage": 0.8, "method": "v4.1", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); width = the company's own volatility of yearly growth, credibility-weighted against its size class (Buhlmann), scaled to the 80% target on 2023 and tested on 2024", "calibratedOn": { "companyYears": 4309, "sizeBand": "$100M–1B", "fitYears": [ 2018, 2022 ], "tuneYear": 2023, "testYear": 2024, "coverageOnTestYear": 0.8341 }, "credibility": { "weightOnOwnRecord": 0.25, "growthYears": 2, "ownVolatility": 0.22949104646635365, "classVolatility": 0.1022985825903761, "pricedVolatility": 0.14496649648127502, "k": 3 }, "stress": { "low": 73644470.19016992, "high": 151323501.55583054, "basis": "the same range with widths set to hold 80% across 2018-2023, pandemic years included" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 2, "hits": 2, "rate": 1, "method": "v4", "byYear": { "2024": [ 1, 1 ], "2025": [ 1, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-24T14:19:37.798Z", "hash": "1e71ac1caf08ef64", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001937653.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1937653" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }